ArticleNPJ precision oncology2025
Clinicopathological and molecular analysis of a dermatofibrosarcoma protuberans with fibrosarcomatous transformation in the breast.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue sarcoma with low potential for metastases. To date, only a few cases of DFSP in the breast have been reported, and none have reported comprehensive genetic signatures. We report, for the first time, the largest DFSP in the breast with multidisciplinary tumor board discussion and comprehensive molecular analysis. This DFSP is 18.5 cm with fibrosarcomatous transformation, distinct gene rearrangement translocation t(17;22) (q22;q13), COL1A1::PDGFB fusion, and subsequent segmental amplification of chromosomes 17q and 22q. The high-level of amplifications of genomic regions containing the COL1A1 and PDGFB genes (6 copies) compared to the reported DFSP cases (2-3 copies) supports the gene dosage effect correlated with aggressive behavior and high-grade tumor histology. This case highlights the importance of precise genetic alteration in the clinicopathological and phenotypic expression of DFSP with fibrosarcomatous transformation, and it helps guide clinical management and informs the role of targeted therapy.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.